Recombinant Human F13B Protein, Glycoengineered Human Cell Lines

Recombinant Human F13B protein (NP_001985.2) is produced in Glycoengineered Human Cell Lines. This expression system is used for the production of glycoproteins and antibodies with human post-translational modifications.

Glycoengineered Human Cell Lines

Human

His-tag, FC-tag

>90%, determined by SDS-PAGE.

Regular batch

None

F13B

Coagulation factor XIII B chain

This gene encodes coagulation factor XIII B subunit. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as a plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon activation by the cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion.

FXIIIB